Previous 10 | Next 10 |
2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...
2024-04-30 11:56:42 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S. FDA approves Alvotech bios...
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration in...
2024-04-26 14:09:10 ET More on AbbVie AbbVie Inc. (ABBV) Q1 2024 Earnings Call Transcript AbbVie's Q1: Positive Surprise AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie Q1 report beats Street despite plunging Humira sales ...
2024-04-24 07:15:00 ET Summary Sound Shore Fund, Inc. is registered as a diversified, open-end management investment company. The investment objective of the Fund is growth of capital. The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10%, respecti...
2024-04-22 10:55:53 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...
2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...
2024-04-19 06:55:31 ET More on Alvotech Alvotech (ALVO) Q4 2023 Earnings Call Transcript FDA approves Alvotech biosimilar of J&J top-selling drug Stelara Alvotech/Teva win FDA approval for Humira biosimilar Seeking Alpha’s Quant Rating on Alvotech ...
2024-04-19 05:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...